Treating wet AMD with radiation

Article

A single procedure may be as effective as repeated anti-VEGF injections claims Timothy L. Jackson.

Key Points

Choroidal neovascularization (CNV) is a result of over-expression of vascular endothelial growth factor, recruitment of inflammatory cells, and fibroblasts. Radiation is known preferentially to damage proliferating endothelial cells. Epimacular brachytherapy is an AMD therapy that utilizes a novel surgical device to deliver targeted beta radiation to active AMD lesions. Unlike anti-VEGF agents, radiation is thought to eliminate CNV vessels permanently, rather than simply suppress them. For this reason, the device offers the prospect of a one-off operation, rather than a lifetime of intravitreal injections entailing considerable expense, patient inconvenience, and a small but cumulative risk of complications.

Early studies of radiation

Successive attempts to provide a more focal delivery under the retina had only limited success, as the very process of accessing the subretinal space caused damage. By contrast, epimacular brachytherapy - which involves the delivery of beta radiation via a vitrectomy procedure - has the potential to provide a highly targeted delivery of beta radiation without surgical damage to the retina.

Details of the procedure

The device consists of a hand piece with a 20-gauge cannula, within which resides a retractable radiation source (the radioactive isotope strontium-90).

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.